CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.
Humans
Temozolomide
/ pharmacology
Glioblastoma
/ drug therapy
Carmustine
/ pharmacology
ATP Binding Cassette Transporter, Subfamily G, Member 2
/ metabolism
Lomustine
/ therapeutic use
CRISPR-Cas Systems
ATP-Binding Cassette Transporters
/ metabolism
Neoplasm Proteins
/ metabolism
Cell Line, Tumor
Drug Resistance, Neoplasm
ATP Binding Cassette Transporter, Subfamily B
/ genetics
ABC transporters
CRISPR
Drug resistance
Glioblastoma
Temozolomide
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
19
08
2022
revised:
10
10
2022
accepted:
10
10
2022
pubmed:
18
10
2022
medline:
9
11
2022
entrez:
17
10
2022
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is the most common malignant brain tumor with limited therapeutic options. Besides surgery, chemotherapy using temozolomide, carmustine or lomustine is the main pillar of therapy. However, therapy success is limited and prognosis still is very poor. One restraining factor is drug resistance caused by drug transporters of the ATP-binding cassette family, e.g. ABCB1 and ABCG2, located at the blood-brain barrier and on tumor cells. The active efflux of xenobiotics including drugs, e.g. temozolomide, leads to low intracellular drug concentrations and subsequently insufficient anti-tumor effects. Nevertheless, the role of efflux transporters in GBM is controversially discussed. In the present study, we analyzed the role of ABCB1 and ABCG2 in GBM cells showing that ABCB1, but marginally ABCG2, is relevant. Applying a CRISPR/Cas9-derived ABCB1 knockout, the response to temozolomide was significantly augmented demonstrated by decreased cell number (p < 0.001) and proliferation rate (p = 0.04), while apoptosis was increased (p = 0.04). For carmustine, a decrease of cells in G1-phase was detected pointing to cell cycle arrest in the ABCB1 knockout (p = 0.006). For lomustine, however, loss of ABCB1 did not alter the response to the treatment. Overall, this study shows that ABCB1 is involved in the active transport of temozolomide out of the tumor cells diminishing the response to temozolomide. Interestingly, loss of ABCB1 also affected the response to the lipophilic drug carmustine. These findings show that ABCB1 is not only relevant at the blood-brain barrier, but also in the tumor cells diminishing success of chemotherapy.
Identifiants
pubmed: 36252775
pii: S1043-6618(22)00456-X
doi: 10.1016/j.phrs.2022.106510
pii:
doi:
Substances chimiques
Temozolomide
YF1K15M17Y
Carmustine
U68WG3173Y
ATP Binding Cassette Transporter, Subfamily G, Member 2
0
Lomustine
7BRF0Z81KG
ATP-Binding Cassette Transporters
0
Neoplasm Proteins
0
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106510Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.